Data & Statistics
Sickle cell disease (SCD) affects millions of people throughout the world and is particularly common among those whose ancestors came from sub-Saharan Africa; Spanish-speaking regions in the Western Hemisphere (South America, the Caribbean, and Central America); Saudi Arabia; India; and Mediterranean countries such as Turkey, Greece, and Italy.
Did you know?
Sickle cell disease occurs more often among people from parts of the world where malaria is or was common. It is believed that people who carry the sickle cell trait are less likely to have severe forms of malaria.
In the United States
The exact number of people living with SCD in the U.S. is unknown. Working with partners, the CDC supports projects to learn about the number of people living with SCD to better understand how the disease impacts their health.
It is estimated that:
- SCD affects approximately 100,000 Americans.
- SCD occurs among about 1 out of every 365 Black or African-American births.
- SCD occurs among about 1 out of every 16,300 Hispanic-American births.
- About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).
- People with SCD have less access to comprehensive team care than people with genetic disorders such as hemophilia and cystic fibrosis. [Read article]
- Sickle cell-related death among Black or African-American children younger than 4 years of age fell by 42% from 1999 through 2002. This drop coincided with the introduction in 2000 of a vaccine that protects against invasive pneumococcal disease.
- Relative to the rate for the period 1983 through 1986, the SCD mortality rate for the period 1999 through 2002 decreased by:
- 68% at age 0 through 3 years;
- 39% at age 4 through 9 years; and
- 24% at age 10 through 14 years.
- Mortality Among Children with Sickle Cell Disease Identified by Newborn Screening During 1990-1994 — California, Illinois, and New York:
- Among the children with Hb SS disease, 1% died as a result of SCD-related causes during the first 3 years of life.
- In California and Illinois, by the end of 1995, the cumulative mortality rate was 1.5 per 100 Black or African-American children with SCD. The equivalent cumulative mortality rate for all Black or African-American infants born during this period in California and Illinois was 2.0 per 100 Black or African-American newborns.
- During 2005, medical expenditures for children with SCD averaged $11,702 for children with Medicaid coverage and $14,772 for children with employer-sponsored insurance. About 40% of both groups had at least one hospital stay.
- SCD is a major public health concern. From 1989 through 1993, an average of 75,000 hospitalizations due to SCD occurred in the United States, costing approximately $475 million.
Key Findings: CDC’s Sickle Cell Data Collection Program Data Useful in Describing Patterns of Emergency Department Visits by Californians with Sickle Cell Disease (SCD)
This study used data from the Sickle Cell Data Collection Program to describe California’s SCD population’s use of the Emergency Department.
(Published: January 31, 2017)
Key Findings: Sickle Cell Disease in California and Georgia: New Death Rate Estimates
This study estimated death rates among people with sickle cell disease (SCD) by matching up data from studies that monitor all people with SCD in a population with state death records from California and Georgia. Learn more about what was found.
(Published: March 25, 2016)
Key Study Findings: Are family physicians comfortable treating people with sickle cell disease?
Are family physicians comfortable treating people with sickle cell disease?
(Published: May 22, 2015)
Incidence of Sickle Cell Trait in the US
Researchers from CDC examined data collected by newborn screening programs to get up-to-date measures of the occurrence of sickle cell trait among newborns by race/ethnicity and state of birth.
(Published: December 11, 2014)
Key Study Findings: Invasive Pneumococcal Disease among Children with and without Sickle Cell Disease in the United States, 1998-2009
Invasive Pneumococcal Disease among Children with and without Sickle Cell Disease in the United States, 1998-2009
(Published: October 18, 2013)
Key Finding: Is hydroxyurea treatment associated with lower medical costs for young children with sickle cell anemia?
The journal Pediatrics has published the first study to look at the costs and health outcomes (cost-effectiveness) of hydroxyurea (HU) treatment in young children with sickle cell disease (SCD).
(Published: September 6, 2013)
Mortality in Adults with Sickle Cell Disease
The link between death and pre-ESRD care in people with ESRD.
(Published: December 4, 2012)
CDC Raising Awareness of Sickle Cell Disease
Find out how you can help by reading and sharing our resources, and by joining the conversation online.
(Published: September 12, 2016)
New Resources in Sickle Cell Trait Toolkit!
The Sickle Cell Trait Toolkit provides valuable information for people with SCT.
(Published: September 2, 2015)
- Page last reviewed: August 9, 2017
- Page last updated: August 31, 2016
- Content source: